B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Principal Scientist - Discovery Chemistry

Full-Time
$165.3k - $206.6k/yr+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan
Senior
PhD
San Carlos, CA, USA
In PersonOn-site work in San Carlos, California is required.
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • A Ph.D. or equivalent advanced degree in organic chemistry, medicinal chemistry, pharmaceutical chemistry, or a related scientific field, with 6+ years of relevant research experience.
  • Deep expertise in synthetic organic chemistry, preferably in a drug discovery or pharmaceutical research setting.
  • Demonstrated experience designing and synthesizing diverse, project-focused compound libraries to interrogate structure-activity relationship (SAR) and biological hypotheses.
  • Strong experience with parallel, convergent, and/or modular synthesis strategies for rapid compound generation and optimization.
  • Demonstrated ability to independently develop and execute synthetic strategies for novel or challenging chemical matter.
  • Strong chemical intuition, creativity, and problem-solving skills, with the ability to identify unconventional solutions to challenging synthetic and drug discovery problems.
  • Demonstrated ability to integrate chemistry with biological data and use experimental results to inform compound design and research strategy.
  • Ability to effectively manage and prioritize multiple chemistry efforts in a fast-paced, exploratory research environment.
  • Excellent communication and presentation skills, with the ability to clearly articulate chemistry strategies, scientific rationale, results, and recommendations to both technical and non-technical audiences.
  • Ability to work on-site in San Carlos, California.
  • Candidates are expected to maintain an electronic notebook to a high level of data quality.
Responsibilities
  • Spearhead chemistry initiatives to facilitate exploratory research on innovative modalities, targets, and screening strategies.
  • Design and implement targeted and diverse compound libraries to test structure-activity relationship hypotheses and meet project objectives.
  • Develop and apply parallel synthesis techniques to enable swift library creation and iterative optimization.
  • Devise and refine synthetic pathways to ensure efficient diversification and scalability.
  • Utilize structure-activity relationship insights to guide and improve compound optimization.
  • Communicate progress through regular updates while proactively identifying challenges and proposing solutions.
  • Collaborate with cross-disciplinary or cross-functional teams and drive innovation within and beyond the Institute.
  • Contribute to management and operational activities to support strategic objectives of the Institute at the San Carlos site.
  • Manage external chemistry teams.
  • Maintain impeccable electronic laboratory notebook records.
Desired Qualifications
  • Experience with emerging small-molecule modalities, including induced proximity approaches such as molecular glues, bifunctional degraders, or transcriptional modulators.
  • Experience with covalent chemistry and/or covalent drug discovery.
  • Experience designing and synthesizing chemical probes or tool compounds for mechanistic biology.
  • Experience managing external chemistry contract research organizations, including vendor selection, project scoping, technical oversight, and review of deliverables.
  • Experience with computer-aided drug design, structure-based design, molecular modeling, or computational chemistry.
  • Experience working at the interface of chemistry and biology in exploratory or platform research.
  • Experience establishing, outfitting, or scaling a chemistry laboratory and associated capabilities.
  • Familiarity with computer-aided drug design approaches and tools for structure-based drug design, molecular docking, and virtual screening.
  • Familiarity with visual data science tools such as Spotfire.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.